ASX Announcement | 25 November 2026

AdAlta Limited (ASX:1AD)

2026 AGM RESCHEDULED TO 17 DECEMBER 2026

Melbourne, Australia: AdAlta Limited (ASX:1AD) ("AdAlta" or "the Company"), developer of next generation cellular immunotherapies for solid cancers, advises that, the Australian Securities and Investments Commission (ASIC) has granted the Company an extension of time under section 250P of the Corporations Act 2001 (Cth) to hold its 2026 Annual General Meeting (AGM) by 18 December 2026.

The Company sought the extension following ASX's review of the Company's placement capacity, to enable the Company to seek Shareholder approval of its additional 10% placement capacity under ASX Listing Rule 7.1A at the AGM.

Following ASIC's approval and as a result of ASX's review of the Company's placement capacity, the AGM previously scheduled for 2.00pm (AEDT) on Monday, 30 November 2026 has been postponed and will now be held as follows:

Date: Thursday, 17 December 2026

Time: 3.00pm (AEDT)

Location: Piper Alderman, Level 23, 459 Collins Street, Melbourne VIC 300

The AGM will consider the resolutions set out in the original Notice of Meeting dated 30 October 2026, with the addition of one resolution seeking approval of the Company's additional 10% placement capacity under ASX Listing Rule 7.1A.

An addendum to the Notice of Meeting, including updated proxy voting arrangements and further information regarding the business of the AGM, will be provided to Shareholders in due course.

Shareholders with any questions regarding the extension of time or the AGM may contact the Company Secretary.

To view a summary, and engage in discussion about this announcement visit AdAlta's InvestorHub here: https://investorhub.adalta.com.au/link/yzvvmy

This ASX announcement has been authorised for release by the CEO & Managing Director of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)
Tim Oldham
CEO & Managing Director
P: +61 403 446 665
E: ir@adalta.com.au

Cameron Jones
CFO & Company Secretary
P: +61 400 086 399
E: cameron.jones@bio101.com

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its 'East to West' strategy, the Company is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting 'Eastern' innovation in cellular immunotherapies with 'Western' regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialisation.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US$20.3 billion by 2028.

AdAlta's other assets include first in class fusion protein, AD-214, that takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis and WD-34, a novel pan-strain inhibitor of malaria, Babesia and Toxoplasma parasites. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering. WD-34 is seeking grant funding to optimise the molecule format to enable single dose seasonal prophylaxis.

To learn more, please visit: www.adalta.com.au

For more information

Join our InvestorHub

Follow us on LinkedIn

Follow us on X (formerly Twitter)